Boehringer Ingelheim’s (BI) country managing director in South East Asia and South Korea (SEASK), Gerrard McKenna characterizes the recent changes within the family-owned business as “evolutionary” in nature, while highlighting the key role that Singapore plays in capitalizing on the blossoming opportunities in the region.
It seems it’s been a rather eventful time for the family-owned company, particularly with the sale of Roxane, BU swap with Sanofi, and the recent appointment of Hubertus von Baumbach—the first new chairman in 24 years. How have these changes effectively set the tone for BI’s regional managers such as yourself?
"Given all the changes in the industry over the last 10 to 15 years, it’s been clear that BI has needed to diversify its capabilities across a few strategic pillars, which now includes human pharma, animal health, consumer health, and biopharma."
